http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JO-1478-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66829c2f897b172f48979d1f93049c12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a7835926c371330d76b087faa4e8f72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_487311ed303efd2dea2f4b00e571e719 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02d00ef8680e2ffd74cd12fdd8731d3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_981658580f9fc718a8c0c1fe5735fe4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af95749c96ff4ea3b929fa01d8342e73 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J3-00 |
| filingDate | 1986-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1988-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29d2d0a5f7b2d33be583d14025f2550f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2ecf6ef94d98d408ca3cffa5c495944 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_474a01c9234f75241c4897f98c596e52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64566e9224d3f4d1b745d7bcfdb6466a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a839025034c6f33b9eb8dc352b6c05a5 |
| publicationDate | 1988-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JO-1478-B1 |
| titleOfInvention | Legacy of the new androstan-17 beta carboxylic acid |
| abstract | This invention relates to a compound of the formula where x1 represents a hydrogen atom, chlorine, bromine or fluorine. X2 represents a hydrogen atom, chlorine, bromine, or fluorine. X1 represents a beta-hydroxy group, or a beta-chlorine atom or a group - oxo, u2 represents a hydrogen atom, Or a methylene group or an alpha-or beta-methyl group, SH3 represents a hydrogen atom or an acyl group having from 1 to 8 carbon atoms, SH4 represents a hydrogen atom A and a group of (K1 - K5) alkyl or a phenyl group, SH5 represents a hydrogen atom or a group ( (K1 - K5) Alkyl or a group of vinyl, J represents either KU 7U8, or CPU or A, or NU9, where U6 and U8 choose from hydrogen or branched or non-branched chains of hydrocarbons and has 1-8 carbon atoms or A phenyl group, CH6 represents a hydrogen atom or a methyl group, a phenyl or a kenyl, or a cycloquinyl group, optionally substituted by the kle, nitrocarboxy, coxy, halogen, cyanobactyl carboxy, and trifluorimethyl, or the k1-k5 group that is replaced by at least one halogen atom, or A concentrated carboxylic group, or non-concentrated or heterogeneous ring (A, Cup, N) containing 3-10 atoms in the ring system, or group K1 Alkyl substituted with any of one or two of the acyclic or aromatic ring 3, 4, 5 or a ring having 6 members or one or two or three groups concentrated or not focused branched or not branched from a chain of hydrocarbons having from 1 to 18 carbon atoms It represents an individual or double bond. The invention also refers to an intermediate method and materials for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds, and a method for treating inflammatory conditions. |
| priorityDate | 1985-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.